| 临床特征 |
|
| 性别(人数/比例) |
|
| 男 | 52 (61.2%) |
| 女 | 33 (38.8%) |
| 年龄(平均年龄/范围–岁) | 70 (45~86) |
| 饮酒史(人数/比例) |
|
| 有 | 27 (31.8%) |
| 无 | 58 (68.2%) |
| 肿瘤家族史(人数/比例) |
|
| 有 | 26 (30.6%) |
| 无 | 59 (69.4%) |
| 病理分期(人数/比例) |
|
| I期 | 17 (20.0%) |
| II期 | 46 (54.1%) |
| III期 | 22 (25.9%) |
| 部位(人数/比例) |
|
| 胃窦 | 65 (76.5%) |
| 胃窦以外 | 20 (23.5%) |
| 分化程度(人数/比例) |
|
| 低分化 | 45 (52.9%) |
| 高/中分化 | 40 (47.1%) |
| Lauren分型 |
|
| 肠型 | 28 (33.0%) |
| 弥漫型 | 20 (23.5%) |
| 混合型 | 37 (43.5%) |
| HER2状态 |
|
| 阴性 | 85 (100.0%) |
| EBER状态 |
|
| 阳性 | 1 (1.1%) |
| 阴性 | 84 (98.9%) |
| PD-L1 CPS |
|
| <1 | 3 (3.5%) |
| 1~4 | 7 (8.2%) |
| ≥5 | 69 (81.2%) |
| 未测 | 6 (7.1%) |